Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
about
Osteogenic and Neurogenic Stem Cells in Their Own Place: Unraveling Differences and Similarities Between NichesTranslating stem cell research to cardiac disease therapies: pitfalls and prospects for improvementThe implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation.Governing stem cell therapy in India: regulatory vacuum or jurisdictional ambiguity?Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cellsClinical research skills development program in cell-based regenerative medicine.Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration.Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?A single epidermal stem cell strategy for safe ex vivo gene therapy.Human Dermal Fibroblasts Demonstrate Positive Immunostaining for Neuron- and Glia- Specific Proteins.Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?Stem cell therapy: from evidence-based medicine to emotion-based medicine? The long Italian way for a scientific regulationRegulation of cell-based therapies in Europe: current challenges and emerging issuesConcise review: bridging the gap: bone regeneration using skeletal stem cell-based strategies - where are we now?Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures.Stem cell therapies and regenerative medicine in China.Reflections on how wound healing-promoting effects of the hair follicle can be translated into clinical practice.Mesenchymal Stem Cells for Treating Articular Cartilage Defects and Osteoarthritis.Fibrous dysplasia of bone: craniofacial and dental implications.Therapeutic potential of neural stem cells: greater in people's perception than in their brains?Marketing of unproven stem cell-based interventions: A call to action.Stem Cells and Tissue Niche: Two Faces of the Same Coin of Muscle Regeneration.A brief perspective on neural cell therapy.Stem cell origin differently affects bone tissue engineering strategies.Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis.Reply to MSCs: science and trials.Research Translation and Emerging Health Technologies: Synthetic Biology and Beyond.Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?Living with Keratinocytes
P2860
Q26774819-7C0D8996-64FD-4598-9287-62D0705CB791Q26860340-78EB4A1F-9322-443A-A2EE-7546C49ABE24Q30424407-9915A19F-3EF2-4C15-92CD-6DB9AFBE5D0CQ34481894-FF15093E-06E7-4A19-9C63-50C227FBE237Q34768188-3027FDC1-7036-4172-B2F5-4FF59196EDB7Q35001367-04436437-7E11-4C0D-8DBA-6ACD02F546D2Q35168406-AC180854-442C-42CA-94D9-F98B4EB39CAFQ35240062-BC73E3EF-6FFA-415C-B6E1-C04F4BF941C6Q35483739-5482409C-D035-4A49-8A6E-D0A78CE8D31DQ35871811-A9A0C0D0-35EA-4AEF-B710-D792736FBF37Q35966394-DB25264A-FC17-41EE-9CEF-755FFD1B6414Q37372177-B1DBB64C-10C2-4C07-B013-5873054645B9Q37442918-6F43BE0C-4FC6-4016-BC6B-A54D208CE757Q38151642-1FE911DB-6B83-4A0D-93DF-2D8BB465B8A7Q38165928-F73A9A1A-09D6-43F8-B26C-4BC984BE49F8Q38178875-A1974A68-8F20-4A6E-99AF-A98F3FB0E744Q38234412-A38B7384-96F1-4DF4-A50D-9BDFC08E6E0FQ38246799-36327861-C5E2-4C1A-9411-6205FF3404BFQ38919235-8C1065E9-F9CD-4A8C-8416-DB480DC63FF1Q38921243-94C4C804-D310-4578-8F30-E2CE7B1964FAQ39416083-F27FC8D5-E02A-47F0-88E0-E6F1A6BC62DBQ40966771-49C5CCCB-560E-4BC4-8CDF-B08CF55F7D7DQ41549791-50251FEC-01AB-42D2-9BC4-96FFF6D69F89Q41852995-60E86AB8-D025-4439-A42D-3C50DCE4F564Q42057790-C11DFB75-8951-4377-A173-03E41340B85EQ44115954-83BA9C80-1126-413E-9D96-9204CA793EFFQ48164591-B06DC5C9-04C9-4BD6-A516-AD60128B61A1Q50224283-9E03C341-2E70-47F2-8889-504D0642C85CQ59136732-E264ADF6-21B3-4434-B37D-B7A9D307A250
P2860
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
@en
type
label
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
@en
altLabel
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls
@en
prefLabel
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
@en
P2093
P2860
P50
P356
P1433
P1476
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
@en
P2093
Austin Smith
Clara Sattler de Sousa E Brito
Hans Clevers
Lawrence Goldstein
Michele De Luca
Oliver Brüstle
Olle Lindvall
Paolo Bianco
P2860
P304
P356
10.1038/EMBOJ.2013.114
P407
P577
2013-05-03T00:00:00Z